Advances in Bioscience and Biotechnology

Advances in Bioscience and Biotechnology

ISSN Print: 2156-8456
ISSN Online: 2156-8502
www.scirp.org/journal/abb
E-mail: abb@scirp.org
"Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments"
written by Diana Gil, Adam G. Schrum,
published by Advances in Bioscience and Biotechnology, Vol.4 No.4A, 2013
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] A 33-residue peptide tag increases solubility and stability of Escherichia coli produced single-chain antibody fragments
Nature …, 2022
[2] Biodistribution and Activity of EGFR Targeted Polymeric Micelles Delivering a New Inhibitor of DNA Repair to Orthotopic Colorectal Cancer Xenografts with Metastasis
Molecular …, 2022
[3] Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Kok, D Panella, AM Georgoudaki… - Journal of Hematology & …, 2022
[4] Nanobody-based CAR-T cells for cancer immunotherapy
Biomarker …, 2022
[5] Improvement in the binding specificity of anti-isomiroestrol antibodies by expression as fragments under oxidizing conditions inside the SHuffle T7 E. coli cytoplasm
Bioscience …, 2022
[6] Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
BioImpacts …, 2022
[7] NMDA-receptor-Fc-fusion constructs neutralize anti-NMDA receptor antibodies
bioRxiv, 2022
[8] Emerging applications of nanobodies in cancer therapy.
International review of …, 2022
[9] Development of antibody therapeutic approaches for poultry diseases using avian influenza as a disease model
2022
[10] Charakterisierung bi-und trispezifischer antiCD40 Antikörper-Fusionsproteine
2022
[11] Herstellung und Charakterisierung von anti-CD40-und anti-41BB-Fusionsproteinen mit PDL1-abhängiger agonistischer Aktivität
2022
[12] Natural Killer Cell Immune Engagers to Induce Optimal Anti-Tumor Activity
2021
[13] Productıon of Recombınant Antıbody Fragments in Bacterıa and Theır Development Towards Medıcal Dıagnosıs
2021
[14] Development of BCMA-specific engineered T cells targeting multiple myeloma
2021
[15] Natural Receptor-and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
Cells, 2021
[16] CAR-NK Cells in the Treatment of Solid Tumors
2021
[17] IL13R⍺ 2-CAR T cells for Immunotherapy of Glioblastoma
2021
[18] The Application of Nanobody in CAR-T Therapy. Biomolecules 2021, 11, 238
2021
[19] Autoinduction as Means for Optimization of the Heterologous Expression of Recombinant Single-Chain Fv (scFv) Antibodies
2021
[20] Machine Learning Feature Selection for Predicting High Concentration Therapeutic Antibody Aggregation
2021
[21] Autoimmune encephalitis: novel therapeutic targets at the preclinical level
2021
[22] The Application of Nanobody in CAR-T Therapy
2021
[23] The antigen‐binding moiety in the driver's seat of CARs
2021
[24] Protection of Alcohol Dehydrogenase against Freeze–Thaw Stress by Ice-Binding Proteins Is Proportional to Their Ice Recrystallization Inhibition Property
2020
[25] Live long and active: Polypeptide-mediated assembly of antibody variable fragments
2020
[26] CAR-T design: Elements and their synergistic function
2020
[27] Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments
2020
[28] Development of active tumor targeting systems for delivery of siRNA and drugs into breast and colorectal cancer
2020
[29] Public and private human T cell clones respond differentially to HCMV antigen when boosted by CD3 co-potentiation
2020
[30] Driving CARs with alternative navigation tools–the potential of engineered binding scaffolds
2020
[31] CAR-T-Zellen erkennen und eliminieren den Thyreotropin-Rezeptor exprimierende differenzierte Schilddrüsenkarzinomzellen
2020
[32] Calcium-dependent affinity ligands for protein purification
2020
[33] ШАПЕРОННАЯ И ИММУНОГЛОБУЛИНСВЯЗЫВАЮЩАЯ АКТИВНОСТИ Skp ИЗ Yersinia pseudotuberculosis
2020
[34] Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody FragmentsVHH-Secreting CAR T Cells
Cancer immunology …, 2020
[35] Advances in point-of-care testing for cardiovascular diseases
2020
[36] Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation
2020
[37] Development of recombinant antibody fragments for toxin and microbial contaminant detection and investigations of microcystin and azaspiracid toxicity.
2019
[38] Exploring and exploiting the minor pilins of Type IV pili
2019
[39] Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development
2019
[40] Chaperone and Immunoglobulin-Binding Activities of Skp Protein from Yersinia pseudotuberculosis
Biochemistry (Moscow), 2019
[41] Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex
2019
[42] Ice-recrystallization inhibiting polymers protect proteins against freeze-stress and enable glycerol-free cryostorage
Materials Horizons, 2019
[43] Amino acid induced hyper activation of laccase and its application in dye degradation
2019
[44] Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono-and Bi-specific Antitumor Activity of T Cells
2019
[45] Improving developability of an Antigen Binding Fragment by Aspartate Substitutions
2019
[46] An Antibody Fab Fragment-based Chimeric Antigen Receptor Could Efficiently Eliminate Human Thyroid Cancer Cells
2019
[47] Design and Production of Bispecific Antibodies
2019
[48] Developing VHH-based tools to study Ebolavirus infection
2019
[49] Pre-clinical development of novel ROR1 chimeric antigen receptor T cells and bispecific T cell engagers
2018
[50] Introduction into Novel Constructs
Challenges in Protein Product Development, 2018
[51] Expression of a functional intrabody against hepatitis C virus core protein in Escherichia coli and silkworm pupae
Protein Expression and Purification, 2018
[52] Strategies to Address Chimeric Antigen Receptor Tonic Signaling
2018
[53] Expression and neutralization capacity of single domain HIV antibody fragments
2018
[54] Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
mAbs, 2018
[55] Bacterial communities adapted to higher external resistance can reduce the onset potential of anode in microbial fuel cells
2018
[56] Optimizing Antibody Expression: the nuts and Bolts
Methods, 2017
[57] Development of humanized scFv antibody fragment (s) that targets and blocks specific HLA alleles linked to myasthenia gravis
Applied Microbiology and Biotechnology, 2017
[58] Molecular Effects of Concentrated Solutes on Protein Hydration, Dynamics, and Electrostatics
Biophysical Journal, 2016
[59] Antibody Aggregation: Insights from Sequence and Structure
Antibodies, 2016
[60] Testing the anti-fibrotic potential of the single-chain Fv antibody against the α 2 C-terminal telopeptide of collagen I
Connective tissue research, 2013
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top